August 4, 2021

WHO grants emergency license to Chinese Sinovac’s vaccine

On the planet, countries are gradually reopening, as vaccine campaigns develop. UK health services did not even record, Tuesday 1is June, no additional deaths from Covid-19 in twenty-four hours, a first since July 30, 2020.

The Covid-19 pandemic has killed at least 3.55 million people worldwide since the WHO office in China reported the onset of the disease at the end of December 2019, according to a report established by the ‘Agence France-Presse, from official sources, Tuesday at 10 a.m. The United States remains the most bereaved country with nearly 600,000 dead, ahead of Brazil (over 450,000 dead) and India (over 300,000).

These figures, which are based on daily reports from national health authorities, are generally underestimated. By taking into account the excess mortality directly and indirectly linked to Covid-19, the World Health Organization (WHO) estimates that the real toll is “Two to three times higher”.

  • WHO approves Chinese CoronaVac vaccine in emergency

The WHO on Tuesday gave its emergency approval to Coronavac, the Chinese vaccine against Sinovac’s Covid-19, according to a statement. The WHO vaccine expert committee has recommended the vaccine, which requires two doses at two to four week intervals, for people 18 years of age and older.

It is the second Chinese vaccine to thus obtain the green light from the WHO – after Sinopharm, approved on May 7 -, which makes it possible in particular to integrate it into the Covax international system for the distribution of vaccines in disadvantaged countries. “The world is in desperate need of many Covid-19 vaccines to cope with the huge inequalities around the world”, said Dr Mariangela Simao, WHO Assistant Director-General in charge of access to medicines and health products. This vaccine – of the inactivated vaccine type – “Is easy to store, which makes it easy to manage and particularly suitable for countries with few resources”, emphasizes the agency.

The Chinese Sinovac vaccine is used in a public hospital in Montevideo (Uruguay) in March 2021.
Article reserved for our subscribers Read also Vaccines against Covid-19, China’s new diplomatic weapon

The effectiveness of CoronaVac is 57% to prevent symptomatic Covid-19 cases and 100% to avoid the most serious cases and hospitalizations, on the populations studied, specifies the WHO. Effectiveness for those over 60 years of age could not, however, be assessed. Besides China, this product is already used in Tunisia, Chile, Brazil, Indonesia, Mexico, Thailand and Turkey.

  • Moderna seeks full authorization for its vaccine in the United States

A vial of the Moderna vaccine, in New York (United States), in January 2021.

Moderna filed a request for full authorization of its Covid-19 vaccine on Tuesday with the US Medicines Agency for people 18 years of age and over. The vaccine has been authorized since December 18 ” emergency “ in the United States, a procedure that made it possible to respond to the health crisis quickly. More than 124 million doses of Moderna’s vaccine have since been administered across the country, according to data from the Centers for Disease Control and Prevention, the country’s main federal public health agency.

Read also: Covid-19: US health agency examines Moderna vaccine for authorization

An emergency authorization is justified “On the best available evidence” without waiting for long-term monitoring data, necessary for full authorization, explains the American regulator on its website. An emergency authorization, issued under conditions, can be revoked or modified at any time depending on the new data collected.

“We are happy to announce this important step”, said the boss of Moderna, Stéphane Bancel, quoted in a press release. The American biotechnology company “Will continue to provide data (…) continuously over the next few weeks ” to health authorities to support her request, she said. Pfizer-BioNTech laboratories also submitted a full authorization request for their own vaccine against Covid-19 in early May in the United States, for people 16 years of age and over.

  • France expects fewer doses than expected in June

A vaccination center in Garlan, western France, in May 2021.

France is expecting the delivery of around 28 million doses of vaccine during the month of June, below the 32 million expected according to the latest forecasts, the economy ministry said on Tuesday. “This revision does not call into question our vaccination objectives for June 15 [30 millions de premières injections] nor the vaccination campaign ”, however wanted to relativize Bercy.

The latest forecasts were for a total of 76.7 million doses received at the end of June for the four vaccines authorized in Europe (since the first deliveries in December). This total will therefore be reduced by around 4 million. “This is explained by the updating of forecasts [pour le vaccin] the Janssen », after the blocking in April of batches of active substances from the United States to Europe, added the Ministry of the Economy.

Article reserved for our subscribers Read also How vaccine orders illustrate the new global geopolitics of health

This blockage followed problems of non-compliance in an American plant of the firm Emergent BioSolutions, located in Baltimore (Maryland). “We reaffirm our global commitment to deliver 200 million doses of our vaccine to the EU, plus Norway and Iceland”, reassured, Tuesday, a spokesperson for Johnson & Johnson.

The World with AFP